HRSA delays effective date of final rule on 340B drug ceiling prices to March 21
The Health Resources and Services Administration today delayed, in accordance with a recent White House memorandum, the effective date of its final rule on drug ceiling prices and civil monetary penalties for manufacturers in the 340B Drug Pricing Program from March 6 to March 21. “The temporary delay in the effective date of this final rule is necessary to give Department officials the opportunity for further review and consideration of new regulations, consistent with the Assistant to the President and Chief of Staff’s memorandum,” the notice states.
Related News Articles
Headline
The Medicare Payment Advisory Commission met April 9 and 10 to discuss several topics, including the relationship between Medicare Advantage enrollment and…
Headline
The Centers for Medicare & Medicaid Services issued an updated registration link for its webinar April 16 at 3 p.m. ET on Medicare Clinical…
Perspective
Few patient populations are more vulnerable to the shifting winds around health care today than Medicare beneficiaries who need specialized, high-acuity and…
Headline
The U.S. Court of Appeals for the 5th Circuit April 9 affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin…
Headline
The Centers for Medicare & Medicaid Services April 6 released the Medicare Advantage and Part D Rate Announcement for calendar year 2027. The rate…
Headline
The U.S. District Court for the District of Columbia March 31 vacated a Health Resources and Services Administration policy instituted in 2013 that restricted…